Search
Ozanimod
go.drugbank.com/drugs/DB12612ApprovedInvestigationalIt was developed by Celgene (now acquired by Bristol-Myers Squibb) [L11025] and was approved by the FDA on March 26, 2020. … [L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020.
Halazepam
go.drugbank.com/drugs/DB00801ApprovedIllicitWithdrawn[A1212, A178114] It has been shown to be less toxic than chlordiazepoxide or diazepam. … [A1212] This drug is no longer marketed in the United States, and was withdrawn by _Schering_, its manufacturer, in 2009.[L6226, L6229]
Serdexmethylphenidate
go.drugbank.com/drugs/DB16629Approved[L32298, L32323] Serdexmethylphenidate was granted FDA approval on March 2, 2021, and is currently marketed as a combination capsule with [dexmethylphenidate] under the trademark AZSTARYS™ by KemPharm … such as [methylphenidate] and [amphetamine] that increase extracellular dopamine and norepinephrine levels.
Blinatumomab
go.drugbank.com/drugs/DB09052ApprovedInvestigational[L44311] Full approval for this indication was granted in June 2023. … Since blinatumomab has an affinity to both antigens, it redirects T-cells to tumor cells expressing CD19 and promotes tumor cell lysis and apoptosis.
Omidenepag isopropyl
go.drugbank.com/drugs/DB15071ApprovedThe use of an EP2 receptor agonist such as omidenepag represents an alternative in these scenarios. Omidenepag IOP-lowering effect is comparable to the one observed with [latanoprost]. … [A253253] In 2018, omidenepag isopropyl was approved in Japan for the treatment of glaucoma and ocular hypertension.[A253268] In September 2022, the FDA approved the use of omidenepag isopropyl.
Prussian blue
go.drugbank.com/drugs/DB06783ApprovedIt is orally administered for clinical purposes to be used as an antidote for certain kinds of heavy metal poisoning, such as thallium and radioactive isotopes of caesium. … Prussian blue is described as a deep blue pigment that is produced when the oxidation of ferrous ferrocyanide salts occurs.
Quizartinib
go.drugbank.com/drugs/DB12874ApprovedInvestigational[A260641] Quizartinib was approved by the FDA in July 2023 and developed under the brand name VANFLYTA by Daiichi Sankyo. … Quizartinib is an oral and potent fms-like tyrosine kinase 3 (FLT3) inhibitor and it is the first drug developed specifically targeting FLT3, as other agents with FLT3 inhibition activities were investigated
Penpulimab
go.drugbank.com/drugs/DB16747ApprovedInvestigationalThe use of an IgG1 backbone - as opposed to an IgG4 backbone as is typical in other anti-PD-1 antibodies like [nivolumab] - is intended to reduce the risk of immune-related adverse events. … [A273843,A273848] Penpulimab-kcqx was approved by the US FDA in April 2025 for the treatment of nasopharyngeal carcinoma in select patients.[L52993,L52998]
Cethromycin
go.drugbank.com/drugs/DB06419Investigational[L13988] It has also been investigated, by itself or together with [zoliflodacin], for the treatment of gonorrhea,[A203432, A203495] and was recently suggested as a possible treatment for liver-stage _ … [L14006, A203369] However, after completing phase III clinical trials, it was deemed safe but not sufficiently efficacious by the FDA.
Cinnamyl alcohol
go.drugbank.com/drugs/DB14186ApprovedDue to the low levels found in cinnamon, cinnamyl alcohol is usually supplied as [DB14184] within commercial products. … Cinnamyl alcohol has been shown to be a skin sensitizer, with a NOEL (No Effect Level) of ~4% [A34266]. Sensitivity to cinnamyl alcohol may be identified with a clinical patch test.